2/2024
vol. 111
Review article
Good or bad? Botulinum toxin in hidradenitis suppurativa
Tomasz Muszyński
3, 4, 5
,
- Doctoral School, Medical University of Silesia, Katowice, Poland
- Department of Dermatology, Medical University of Silesia, Katowice, Poland
- Doctoral School of Medical and Health Sciences, Jagiellonian University Medical College, Krakow, Poland
- 1st Department of General and Oncological Surgery, Jagiellonian University Medical College, Krakow, Poland
- Department of Vascular Surgery, St. John Grande’s Hospital, Krakow, Poland
Dermatol Rev/Przegl Dermatol 2024, 111, 120-124
Online publish date: 2024/09/13
Get citation
PlumX metrics:
Introduction
Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic dermatological condition, characterized by the occurrence of inflammatory nodules, abscesses, fissures and scaring in typical anatomical locations. The pain, pruritus, suppuration and malodour may significantly affect patients’ quality of life. Various treatment methods are used in its management, including both topical and systemic therapies as well as surgical interventions. Botulinum toxin is a neurotoxin, which injected locally blocks the release of acetylcholine at the nerve terminals, resulting in decreasing muscle spasms and reducing the amount of sweat produced by sweat glands [1]. Injections of botulinum toxin are widely used in dermatology [2] e.g. in treating hyperhidrosis [3], reducing facial wrinkles [4], treating chronic anal fissure [5] and other conditions.
Objective
Our aim was to analyse current evidence on botulinum toxin use in the treatment of HS.
Methods
We performed a review of the literature in Embase and Medline databases, including key words such as “botulinum toxin”, “Botox”, “hidradenitis suppurativa” and “acne inversa”. The search was as broad as possible, including EMTREE and MESH approaches, conducted according to the PRISMA guidelines. The following inclusion criteria were applied: original trials, case reports, case series with botulinum toxin use in HS treatment, with or without any concomitant treatment methods, published in English until May 2022. 18 results were identified in Embase, 1 in Medline and 50 in both databases and given further analysis with additional manual research. 8 articles including 28 patients were included in the final analysis.
Results
The results that matched the inclusion criteria were analysed concerning 1) type of botulinum toxin used, 2) number of units per procedure, 3) HS initial severity and post-procedural results, 4) concomitant therapies, 5) duration of the post-treatment effect, 6) patients’ quality of life. Analysed issues are shown in Table 1 [6–13].
Discussion
Hidradenitis suppurativa, also known as acne inversa, is a chronic inflammatory skin condition that mainly affects areas rich in apocrine sweat glands, such as the armpits, groin, buttocks and the area under the breasts. It often manifests as painful nodules, abscesses, sinuses and scarring. The exact cause of HS is not fully understood, but it is believed to involve a combination of genetic, immunological and environmental factors. Treatment of HS typically involves a multidisciplinary approach tailored to the severity and extent of the disease. Typical treatments include topical therapies, systemic therapies, biologic therapies, surgical interventions and lifestyle modifications. Our review was designed to assess whether botulinum toxin can be effective in the treatment of acne inversa. All reports confirmed a beneficial effect on the course of HS, and consequently on patients’ quality of life. Eight articles covering 28 patients from 2009-2023 were included in the final analysis. Toxin type A (papers by authors Nienstedt et al. [6], Chen et al. [7], Shi et al. [9], Campanati et al. [10], Khoo et al. [11], Feito-Rodríguez et al. [12], O’Reilly et al. [13]) and B were used (research by Grimstad et al. [8]) in the regions such as axillas (research by Nienstedt et al. [6], Chen et al. [7], Grimstad et al. [8], Shi et al. [9], Campanati et al. [10], O’Reilly et al. [13]), groins (articles by Grimstad et al. [8], Shi et al. [9], Campanati et al. [10], Khoo et al. [11], Feito-Rodríguez et al. [12], O’Reilly et al. [13]), genital area (paper by Grimstad et al. [8]), inner thigh (article by Campanati et al. [10]), and areas including gluteal folds, gluteal cleft, and suprapubic area (research by Khoo et al. [11]). Injections at doses of 40 U, 50 U, 100 U, 250 U per therapeutic area were used. In 5 studies, the injections were performed during a single session; in one study, a series of 4 treatments over 3 years were performed.
Depending on the study, during the follow-up period after applying botulinum toxin, visual improvement, reduction in pain and inflammation, increased mobility and accelerated ability to return to physical activity were noted. Patients’ scores in the Dermatology Life Quality Index (DLQI) also showed positive change.
These promising follow-up results suggest that using botulinum toxin in the treatment of HS may bring benefits with no major side effects. In addition, improvement assessed with DLQI indicate a positive impact of the therapy on patients’ overall quality of life, which is a key aspect in managing a chronic disease like HS. Nevertheless, long-term efficacy and safety studies on larger groups of patients are needed in order to investigate botulinum toxin injection effect in the treatment of HS as it seems to be a valuable therapeutic option for patients with this difficult-to-manage disease.
Conclusions
Both botulinum A and B toxins were found to improve the course of HS; also, botulinum toxin managed to reduce the hyperhidrosis present in some patients. No major side effects were noted during the therapy. The effect lasted for several months. Botulinum toxin seems to be a safe and effective treatment in patients with HS, also improving the patients’ quality of life. It can be either used in monotherapy or combination with other methods of treatment.
Funding
No external funding.
Ethical approval
Not applicable.
Conflict of interest
The authors declare no conflict of interest.
References
1. Montero-Vilchez T., Diaz-Calvillo P., Rodriguez-Pozo J.A., Cuenca-Barrales C., Martinez-Lopez A., Arias-Santiago S.: The burden of hidradenitis suppurativa signs and symptoms in quality of life: systematic review and meta-analysis. Int J Environ Res Public Health 2021, 18, 6709. 2.
Awadeen A., Fareed M., Elameen A.M.: The impact of botulinum toxin injection on the outcomes of breast surgeries: a systematic review and meta-analysis. Aesthetic Plast Surg 2023, 47, 1771-1784. 3.
Obed D., Salim M., Bingoel A.S., Hofmann T.R., Vogt P.M., Krezdorn N.: Botulinum toxin versus placebo: a meta-analysis of treatment and quality-of-life outcomes for hyperhidrosis. Aesthetic Plast Surg 2021, 45, 1783-1791. 4.
Camargo C.P., Xia J., Costa C.S., Gemperli R., Tatini M.D., Bulsara M.K., et al.:. Botulinum toxin type A for facial wrinkles. Cochrane Database Syst Rev 2021, 7, CD011301. 5.
Bobkiewicz A., Francuzik W., Krokowicz L., Studniarek A., Ledwosiński W., Paszkowski J., et al.: Botulinum toxin injection for treatment of chronic anal fissure: is there any dose-dependent efficiency? A meta-analysis. World J Surg 2016, 40, 3064-3072. 6.
Nienstedt R., Rümmelein B.: Adjuvant therapy with laser and botulinum toxin-A in hidradenitis suppurativa. 11th EHSF Conference 2022. Abstract P61-148. 7.
Chen Q., Zhang S., Yang J., Tang J., Li W.: A case report of axillary hidradenitis suppurativa treated with botulinum toxin A. Chin J Plastic Surg 2022, 1047-1049. 8.
Grimstad Ø., Kvammen B.Ø., Swartling C.: Botulinum toxin type B for hidradenitis suppurativa: a randomised, double-blind, place-bo-controlled pilot study. Am J Clin Dermatol 2020, 21, 741-748. 9.
Shi W., Schultz S., Strouse A., Gater D.R.: Successful treatment of stage III hidradenitis suppurativa with botulinum toxin A. BMJ Case Rep 2019, 12, e226064. 10.
Campanati A., Martina E., Giuliodori K., Bobyr I., Consales V., Offidani A.: Two cases of Hidradenitis suppurativa and botulinum toxin ty-pe a therapy: a novel approach for a pathology that is still difficult to manage. Dermatol Ther 2019, 32, e12841. 11.
Khoo A.B., Burova E.P.: Hidradenitis suppurativa treated with Clostridium botulinum toxin A. Clin Exp Dermatol 2014, 39, 749-750. 12.
Feito-Rodríguez M., Sendagorta-Cudós E., Herranz-Pinto P., de Lucas-Laguna R.: Prepubertal hidradenitis suppurativa successfully treated with botulinum toxin A. Dermatol Surg 2009, 35, 1300-1302. 13.
O’Reilly D.J., Pleat J.M., Richards A.M.: Treatment of hidradenitis suppurativa with botulinum toxin A. Plast Reconstr Surg 2005, 116, 1575-1576.
Copyright: © 2024 Polish Dermatological Association. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License ( http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
|
|